#United States #Philadelphia #IntegriChain #Blue Fin Group #Pharma Distribution

IntegriChain and Blue Fin Group Share Pharma Distribution Insights at Informa Conference

In the rapidly evolving landscape of the pharmaceutical industry, IntegriChain, renowned for its expertise in revenue optimization technology, is taking center stage alongside Blue Fin Group at the upcoming Trade & Channel Strategies conference, scheduled for December 10-12 in Philadelphia. This event promises to explore intricate distribution strategies crucial for pharma manufacturers of varying sizes and stages of development.

Keynote Presentation

The keynote session, titled "Access and Channel 2024 Year in Review and Preview of 2025," will be led by Bill Roth, Senior Vice President and Managing Partner of Blue Fin Group. This insightful address is set to take place on Tuesday, December 10, from 8:15 to 9:15 AM ET. Roth will delve into the significant developments within the access and channel landscape over the past year and outline a strategic outlook for the coming year. Attendees can expect an in-depth analysis of the current reimbursement landscape, alongside key challenges and opportunities that lie ahead.

Roth’s session will also touch upon emerging trends regarding site-of-care dynamics that are transforming patient access for various treatments. Moreover, he will review how changes in the cost of goods are shaping company strategies and profitability, providing invaluable best practices for navigating these complexities.

Leveraging AI for Enhanced Insights

Continuing the discussion on innovation, Mike Zubey, Senior Vice President for IntegriChain, will present on Wednesday, December 11, at 11:30 AM to 12:15 PM ET. His session will focus on the transformative power of artificial intelligence in driving channel insights. Zubey aims to share his extensive knowledge on how AI can help pharmaceutical companies manage and analyze data with unprecedented efficiency. By consolidating data from multiple sources, companies can enhance decision-making for both immediate and long-term strategies.

He will also address traditional barriers in therapy development and show how machine learning can uncover hidden correlations in data, thereby supporting better patient care and adherence. This offering is particularly relevant as the industry increasingly turns to advanced data solutions to overcome existing obstacles.

Who's Speaking?

Bill Roth

With over 25 years of experience in the pharmaceutical sector, Bill Roth is a leading expert on healthcare business model development. As the founder of Blue Fin Group in 2001, he has established himself as a vital force in access and commercialization management consulting. Recognized for his ability to predict future trends accurately, Roth has influenced numerous organizations in improving their strategic directions and financial health by directly engaging with a diverse range of business models across the industry.

Mike Zubey

As a key figure in IntegriChain’s sales organization, Mike Zubey has a track record of delivering innovative data solutions in the biotech landscape. His previous role as CEO of BridgeView Life Sciences showcased his leadership in patient data management and analytics before the company’s acquisition by IntegriChain. With an MBA from Villanova University, Zubey is equally committed to education, serving as an adjunct professor and a member of a private equity biotech investment firm.

About IntegriChain

IntegriChain stands at the forefront of the pharmaceutical industry's revenue optimization, utilizing its ICyte data-driven platform to assist manufacturers in formulating sustainable growth strategies. By connecting commercial, financial, and operational facets of drug access, IntegriChain is redefining how pharmaceutical companies approach market demands.
Their commitment is further enhanced through collaborations with leading private equity investors like Nordic Capital, reflecting their robust capabilities across healthcare technology domains. With headquarters in Philadelphia and additional offices in India, IntegriChain continues to cement its stature as a pivotal asset in the pharma landscape.

As the conference approaches, industry professionals are encouraged to gather and share insights crucial for navigating the challenges that lie ahead in the pharmaceutical distribution realm. Don't miss the opportunity to learn from the best in the business and prepare for the future of pharma access and strategy.